Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Autor: Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Weiping Liu, Michele Kosh, NamPhuong Tran, Robin Carson, Pieter Sonneveld

Publikováno v: Blood. 140:7272-7274

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba22a2a40394e83e46ab8ba94dfd9e9f
https://doi.org/10.1182/blood-2022-163483

Effects of altered cellular ultrastructure on energy metabolism in diabetic cardiomyopathy – an in-silico study

Autor: Shouryadipta Ghosh, Giovanni Guglielmi, Ioannis Orfanidis, Fabian Spill, Anthony Hickey, Eric Hanssen, Vijay Rajagopal

Diabetic cardiomyopathy is a leading cause of heart failure in diabetes. At the cellular level, diabetic cardiomyopathy leads to altered mitochondrial energy metabolism and cardiomyocyte ultrastructure. We combined electron microscopy (EM) and comput

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2833a0dd0075c7be73be66a1a93fc59f
https://doi.org/10.1101/2022.05.22.492785

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Autor: Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrian Alegre Amor, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Besisik, Michele Cavo, Javier De La Rubia Comos, Meletios A. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Facon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hajek, Guner Hayri Ozsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Stefan Knop, Marie-Christine Kyrtsonis, Juan Jose Lahuerta, Xavier Leleu, Carmen Martinez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique Minnema, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlivan, Ludek Pour, Henk Th.J. Roerdink, Laura Rosinol Dacsh, Hans Salwender, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tulin Tuglular, Ali Unal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group

Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c27bb717191298826d5623e5b11470
http://hdl.handle.net/10261/261314

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Autor: Ioannis Orfanidis, Philippe Moreau, Maria-Victoria Mateos, Jordan M. Schecter, Jessica Vermeulen, Tobias Kampfenkel, Evangelos Terpos, Jon Ukropec, Mario Boccadoro, Robin Carson, Eirini Katodritou, Albert Oriol, Meral Beksac, Jelena Bila, Yanping Qiu, Himal Amin, Pieter Sonneveld, Argiris Symeonidis, Hermann Einsele, Tahamtan Ahmadi, Sosana Delimpasi, Luca Baldini, Meletios A. Dimopoulos

Publikováno v: Blood. 136:5-6

Introduction Immunomodulatory drug (IMiD)-based regimens are a standard of care (SOC) for RRMM. Daratumumab (DARA) is a CD38-targeted mAb approved for treatment of pts with RRMM. The subcutaneous (SC) formulation of DARA has a similar safety profile

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd94cc27df27a36b6194ec6cf26b8141
https://doi.org/10.1182/blood-2020-135874